As the intravenous administration of solid glass particles could seriously affect patient health(0), Stevanato Group is treating glass delamination with high priority, even if up to now we did not receive any complaint related to our Pharmaceutical Tubular Containers. We also want caution against overreaction and
generalized statements based on specific recent events on the market. It is important to carefully analyze information as not all products are exposed to the same level of delamination risk.
Nevertheless, Stevanato Group is committed to support our customers in order to clarify the situation and to respond to requirements in order to mitigate delamination risk or even to control this phenomenon.